[go: up one dir, main page]

GB202314993D0 - 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations - Google Patents

5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations

Info

Publication number
GB202314993D0
GB202314993D0 GBGB2314993.3A GB202314993A GB202314993D0 GB 202314993 D0 GB202314993 D0 GB 202314993D0 GB 202314993 A GB202314993 A GB 202314993A GB 202314993 D0 GB202314993 D0 GB 202314993D0
Authority
GB
United Kingdom
Prior art keywords
dimethyltryptamine
dmt
meo
methoxy
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2314993.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Priority to GBGB2314993.3A priority Critical patent/GB202314993D0/en
Publication of GB202314993D0 publication Critical patent/GB202314993D0/en
Priority to US18/607,093 priority patent/US12246005B2/en
Priority to PCT/GB2024/051512 priority patent/WO2024256821A1/en
Priority to US19/040,537 priority patent/US20250193970A1/en
Ceased legal-status Critical Current

Links

GBGB2314993.3A 2023-06-13 2023-09-29 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations Ceased GB202314993D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2314993.3A GB202314993D0 (en) 2023-09-29 2023-09-29 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
US18/607,093 US12246005B2 (en) 2023-06-13 2024-03-15 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
PCT/GB2024/051512 WO2024256821A1 (en) 2023-06-13 2024-06-13 Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
US19/040,537 US20250193970A1 (en) 2023-06-13 2025-01-29 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2314993.3A GB202314993D0 (en) 2023-09-29 2023-09-29 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations

Publications (1)

Publication Number Publication Date
GB202314993D0 true GB202314993D0 (en) 2023-11-15

Family

ID=88696339

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2314993.3A Ceased GB202314993D0 (en) 2023-06-13 2023-09-29 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations

Country Status (1)

Country Link
GB (1) GB202314993D0 (en)

Similar Documents

Publication Publication Date Title
IL285537A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
GB202308830D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
EP4595962A3 (en) Pharmaceutical composition
IL285539A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
PT3826632T (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP4329879A4 (en) Novel n,n-dimethyltryptamine compositions and methods
IL315902A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of psychomotor retardation
IL315905A (en) 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation
GB202316902D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
GB202315176D0 (en) 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) formulations
GB202314993D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
GB202306256D0 (en) 5-Methoxy-N,N-Dimethyltryptamine Formulations
GB202400703D0 (en) 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) formulations
GB202505025D0 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
HUE061288T2 (en) Formulations comprising active oxygen
HK40107577A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
HK40065798A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
IL315894A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
PL3902541T3 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
Dan Forewords.
HK40103232A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40065799A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
IL321617A (en) Bezuclastinib formulations
GB202315863D0 (en) Formulations
GB202307059D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)